Pomalyst (Pomalidomide) Patent Expiration, LOE Window & CMS Spending
Pomalyst (Pomalidomide) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2031-12-21, 10 AB generics, $2.25B 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bristol Myers Squibb |
| FDA Application & Pathway | N204026 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-12-21 |
| Last Listed Patent or Exclusivity Date | 2031-12-21 |
| Orange Book Patents (*PED Extensions) | 6 patents (3 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $2.25B |
| 2024 Medicare Part D Spend | $2.15B |
| 2024 Medicaid Spend | $103.7M |
| Reported Wholesale Price Change (CA SB 17) | 24 WAC filings (max 20.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.